TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36179736

Group type: EXPERIMENTAL
Intervention: Oral fexinidazole (1200 mg for 20-34 kg; 1800 mg for 35 kg or more) once per day for 4 days, followed by 600 mg or 1200 mg once per day for 6 days.
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Oral fexinidazole
Number of subjects: 125
Study: 36179758

Group type: EXPERIMENTAL
Intervention: AI-guided screening
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1003
Study: 36179808

Group type: EXPERIMENTAL
Intervention: Stroke subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: CVD controls
Number of subjects: 0
Study: 36180086

Group type: EXPERIMENTAL
Intervention: M1a and M1b patients
Number of subjects: 2082

Group type: COMPARATOR
Intervention: M1c with one to three organs
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: M1b-liver metastases
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Low-risk group (M1a, M1b-non-liver, M1c-1-3-orgsys-non-liver)
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: High-risk group (M1c-liver, M1b-liver, M1c-4+-orgsys)
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Female gender and Eastern Cooperative Oncology Group stage 0
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: T1- or N0-status
Number of subjects: 2082
Study: 36180103

Group type: EXPERIMENTAL
Intervention: Novel investigational treatments for COPD and asthma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing COPD and asthma treatments
Number of subjects: 0
Study: 36180114

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaires for sleep disorders
Number of subjects: 46
Study: 36180329

Group type: EXPERIMENTAL
Intervention: Ixazomib monotherapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ixazomib plus rituximab
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both treatment groups (ixazomib monotherapy and ixazomib plus rituximab)
Number of subjects: 12
Study: 36180379

Group type: EXPERIMENTAL
Intervention: Curative RT
Number of subjects: 301

Group type: COMPARATOR
Intervention: Palliative RT
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Increasing number of geriatric impairments
Number of subjects: 301
Study: 36180844

Group type: EXPERIMENTAL
Intervention: Natural Language Processing (NLP) analysis of self-reported narratives
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Machine Learning (ML) algorithms for classification
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Thematic and sentiment analysis of text
Number of subjects: 121
Study: 36180896

Group type: EXPERIMENTAL
Intervention: Social network visualizations coupled with group Motivational Interviewing (MI)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Pilot workshop sessions with social network visualizations
Number of subjects: 91
Study: 36181587

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy group (CPT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: PTSD coping skills group (PCS)
Number of subjects: 120
Study: 36181605

Group type: EXPERIMENTAL
Intervention: Low AI exposure (AI ratio < 0.40)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Intermediate AI exposure (0.40 ≤ AI ratio ≤ 0.60)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: High AI exposure (AI ratio > 0.60)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: AI exposure (overall)
Number of subjects: 569
Study: 36181952

Group type: EXPERIMENTAL
Intervention: Aerobic fitness intervention (VO2 measurement)
Number of subjects: 936

Group type: COMPARATOR
Intervention: Control group (640 participants)
Number of subjects: 936
Study: 36182027

Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy for Insomnia (BBTI)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Healthy eating attention control
Number of subjects: 158
Study: 36182062

Group type: EXPERIMENTAL
Intervention: Posturography with vision suppression
Number of subjects: 95

Group type: COMPARATOR
Intervention: Posturography without vision suppression
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Postural Assessment Scale for Stroke
Number of subjects: 95
Study: 36182805

Group type: EXPERIMENTAL
Intervention: Proxalutamide 200 mg/day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Proxalutamide 200 mg/day in triple-negative subgroup
Number of subjects: 45
Study: 36183064

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional oxygen and CPAP outside ICU
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: NIV after 48 hours
Number of subjects: 80
Study: 36183100

Group type: EXPERIMENTAL
Intervention: Monthly screening using ultrasensitive rapid diagnostic tests and treatment with dihydroartemisinin-piperaquine (DHA-PQ)
Number of subjects: 340
Study: 36183416

Group type: EXPERIMENTAL
Intervention: Fieldworkers' reciprocity work during the MDA trial
Number of subjects: 0
Study: 36183444

Group type: EXPERIMENTAL
Intervention: Arfolitixorin (30, 60, 120, or 240 mg/m) combined with 5-fluorouracil (5-FU)
Number of subjects: 105
Study: 36183869

Group type: EXPERIMENTAL
Intervention: Access to antibody testing
Number of subjects: 53207

Group type: COMPARATOR
Intervention: Access to c-peptide or genetic testing
Number of subjects: 53207
Study: 36184067

Group type: EXPERIMENTAL
Intervention: Lorlatinib (detailed dosage and duration not specified)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 372
Study: 36184076

Group type: COMPARATOR
Intervention: Isotonic exercise training
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Isometric exercise training
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: High volume isotonic exercise training
Number of subjects: 579
Study: 36184192

Group type: EXPERIMENTAL
Intervention: Bayesian stereotype method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Frequentist high-dimensional feature selection
Number of subjects: 0
Study: 36184219

Group type: EXPERIMENTAL
Intervention: Chloride dipsticks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Creatinine dipsticks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corrected creatinine values
Number of subjects: 0
Study: 36184238

Group type: EXPERIMENTAL
Intervention: Ultrasound meal accommodation test (UMAT) in Group A (without FI)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Ultrasound meal accommodation test (UMAT) in Group B (with FI)
Number of subjects: 61
Study: 36184294

Group type: EXPERIMENTAL
Intervention: Abnormal portal vein flow pulsatility (PPF50) before CPB
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Abnormal portal vein flow pulsatility (PPF50) after CPB
Number of subjects: 373
Study: 36184301

Group type: EXPERIMENTAL
Intervention: Dietary intervention (two healthy diets)
Number of subjects: 540
Study: 36184624

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 1068

Group type: COMPARATOR
Intervention: Active surveillance
Number of subjects: 1068
Study: 36184629

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia preceding general anaesthesia (SPA)
Number of subjects: 636

Group type: COMPARATOR
Intervention: General anaesthesia alone (GA)
Number of subjects: 636
Study: 36184642

Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg + Apatinib 500 mg + Fuzuloparib 100 mg
Number of subjects: 32
Study: 36184730

Group type: EXPERIMENTAL
Intervention: EG (EyeGuidance module)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single image analysis
Number of subjects: 60
Study: 36185070

Group type: EXPERIMENTAL
Intervention: Inpatient screening colonoscopy
Number of subjects: 312
Study: 36185311

Group type: EXPERIMENTAL
Intervention: Nanotechnology-enhanced immunotherapy combined with ferroptosis; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ferroptosis inducers; specific details not mentioned.
Number of subjects: 0
Study: 36185330

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36185388

Group type: EXPERIMENTAL
Intervention: Remote implementation of the Goals for Reaching Optimal Wellness intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36185465

Group type: EXPERIMENTAL
Intervention: 5A score (inflammation-based risk score)
Number of subjects: 3124

Group type: EXPERIMENTAL
Intervention: 5A score
Number of subjects: 3124
Study: 36185653

Group type: EXPERIMENTAL
Intervention: Plasma fatty acid (PFA) levels in adults with moderate or severe COVID-19
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palmitic acid levels in adults with severe COVID-19
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alterations in PFA profiles during COVID-19 infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fatty acids as nutritional targets
Number of subjects: 0
Study: 36185706

Group type: EXPERIMENTAL
Intervention: Intravenous difelikefalin 0.5 μg/kg after each hemodialysis session for 12 weeks
Number of subjects: 222
Study: 36185772

Group type: EXPERIMENTAL
Intervention: Music listening (instrumental Western Classical music)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nature sound control
Number of subjects: 9

Group type: COMPARATOR
Intervention: No sound control
Number of subjects: 9
Study: 36185969

Group type: EXPERIMENTAL
Intervention: Homologous vaccination (three doses of BNT162b2) followed by BNT162b2 booster
Number of subjects: 140

Group type: COMPARATOR
Intervention: Heterologous vaccination (two doses of CoronaVac followed by BNT162b2 booster)
Number of subjects: 140
Study: 36186606

Group type: EXPERIMENTAL
Intervention: Risedronate (n=91)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Weight-bearing/resistance exercise (n=92)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control (n=93)
Number of subjects: 276
Study: 36186648

Group type: EXPERIMENTAL
Intervention: Antenatal COVID-19 infection
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine administration to convalescent mothers
Number of subjects: 34

Group type: COMPARATOR
Intervention: Healthy unrelated controls
Number of subjects: 34
Study: 36186721

Group type: EXPERIMENTAL
Intervention: Riociguat (0.5-2.5 mg three times daily, based on bodyweight)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 24
Study: 36186786

Group type: EXPERIMENTAL
Intervention: New biomarkers for TB outcome prediction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Latent TB infection (Control)
Number of subjects: 60
Study: 36186794

Group type: EXPERIMENTAL
Intervention: Tidal volume of 6 mL/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tidal volume of 8 mL/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tidal volume of 10 mL/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tidal volume of 12 mL/kg
Number of subjects: 10
Study: 36186800

Group type: EXPERIMENTAL
Intervention: Low-protein diet supplemented with ketoacids (LPD + KA)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional low-protein diet (LPD)
Number of subjects: 58
Study: 36186810

Group type: EXPERIMENTAL
Intervention: Topical lidocaine ointment applied twice daily for 2 weeks
Number of subjects: 20
Study: 36186856

Group type: EXPERIMENTAL
Intervention: Mindfulness-based group therapy (Feel-Good intervention), 8 sessions over 8 weeks.
Number of subjects: 36
Study: 36186962

Group type: EXPERIMENTAL
Intervention: Inter-arm systolic pressure difference (IASBPD)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Upstroke time (UT)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Upstroke time per cardiac cycle (UTCC)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Combination of IASBPD and PVR-derived parameters
Number of subjects: 320
Study: 36186982

Group type: COMPARATOR
Intervention: ≥5 live births
Number of subjects: 3454

Group type: COMPARATOR
Intervention: 1-2 live births
Number of subjects: 3454

Group type: COMPARATOR
Intervention: 3-4 live births
Number of subjects: 3454

Group type: COMPARATOR
Intervention: 0 live births (nulliparity)
Number of subjects: 3454
Study: 36187009

Group type: EXPERIMENTAL
Intervention: TAVI
Number of subjects: 97
Study: 36187555

Group type: EXPERIMENTAL
Intervention: TP53-mutations
Number of subjects: 9104

Group type: EXPERIMENTAL
Intervention: Any mutation in the 31 genes (mut31)
Number of subjects: 9104

Group type: EXPERIMENTAL
Intervention: CDKN2A-deletion
Number of subjects: 9104

Group type: EXPERIMENTAL
Intervention: PTEN-deletion
Number of subjects: 9104

Group type: EXPERIMENTAL
Intervention: MYC-amplification
Number of subjects: 9104
Study: 36187722

Group type: EXPERIMENTAL
Intervention: Cytosponge™ assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytosponge™
Number of subjects: 0
Study: 36187760

Group type: EXPERIMENTAL
Intervention: Mitochondrial-targeted antioxidant supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 36187849

Group type: EXPERIMENTAL
Intervention: Healthy Eating for Successful Living in Older Adults™ program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36187926

Group type: EXPERIMENTAL
Intervention: Clinical exome sequencing and collapsing analyses for genetic variants in ARDS samples.
Number of subjects: 515

Group type: COMPARATOR
Intervention: Control group (non-ARDS neonates)
Number of subjects: 515
Study: 36188162

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) telehealth intervention protocol (PREPaRe)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 36188406

Group type: EXPERIMENTAL
Intervention: DHA + EPA supplementation (2.442 g/day DHA and 1.020 g/day EPA)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: DHA + EPA supplementation
Number of subjects: 38
Study: 36188434

Group type: EXPERIMENTAL
Intervention: Caregivers of patients with ECD and other HN
Number of subjects: 0
Study: 36188763

Group type: EXPERIMENTAL
Intervention: Sub-maximal exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36188784

Group type: EXPERIMENTAL
Intervention: Smartphone-based symptom monitoring
Number of subjects: 0
Study: 36188867

Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS) combined with Video Game-Based Training, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, details not available
Number of subjects: 0
Study: 36188922

Group type: EXPERIMENTAL
Intervention: Robotic upper extremity rehabilitation combined with motor cortex anodal tDCS
Number of subjects: 8
Study: 36188946

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) therapy delivered by the MyndMove stimulator, 40 sessions
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 51
Study: 36189008

Group type: EXPERIMENTAL
Intervention: 5-min slow diaphragmatic breathing for 5 weeks, three times/week, with breath science education once/week
Number of subjects: 43

Group type: COMPARATOR
Intervention: Treatment-as-usual control
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 5-min slow diaphragmatic breathing for 5 weeks
Number of subjects: 43
Study: 36189036

Group type: EXPERIMENTAL
Intervention: Personalized practice dosages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care practice dosages
Number of subjects: 0
Study: 36189037

Group type: EXPERIMENTAL
Intervention: Strength training (low-intensity, moderate-intensity, high-intensity based on MEPs) 3X/week for 4 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Real anodal tDCS (2 mA, 20 min)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham anodal tDCS (2 mA, 20 min)
Number of subjects: 90
Study: 36189149

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg hydroxyzine plus 0.5 mg/kg midazolam
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1 mg/kg hydroxyzine plus 0.5 mg/kg midazolam
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0.5 mg/kg midazolam alone
Number of subjects: 45
Study: 36189181

Group type: EXPERIMENTAL
Intervention: Anxious depression with no pain
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Anxious depression with mild to moderate pain
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Anxious depression with severe pain
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Atypical depression in remission
Number of subjects: 158
Study: 36189196

Group type: EXPERIMENTAL
Intervention: High-risk PCI with VA-ECMO support
Number of subjects: 14
Study: 36189333

Group type: EXPERIMENTAL
Intervention: Below elbow cast (BEC)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Above elbow cast (AEC)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Comparison of BEC and AEC
Number of subjects: 280
Study: 36189636

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring (DVR)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 36189747

Group type: EXPERIMENTAL
Intervention: Psoriasis patients with metabolic disorders
Number of subjects: 920

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 920
Study: 36189908

Group type: EXPERIMENTAL
Intervention: Primary dental care (PDC) treatment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study: 36190432

Group type: EXPERIMENTAL
Intervention: siHIF2
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: PT2399
Number of subjects: 1
Study: 36190480

Group type: EXPERIMENTAL
Intervention: Empowering leadership training, direct field experimentation of empowering leadership, and coaching for 12 months.
Number of subjects: 751

Group type: COMPARATOR
Intervention: Control sub-centre without intervention.
Number of subjects: 751
Study: 36190503

Group type: EXPERIMENTAL
Intervention: Impact-induced injuries
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Back injuries
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Neck injuries
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Loss of consciousness
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Impaired capacity to perform job
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Sick leave
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Veterans Affairs disability rating
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Surgery during active duty
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Surgery after leaving active service
Number of subjects: 214
Study: 36190522

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab
Number of subjects: 155
Study: 36190737

Group type: EXPERIMENTAL
Intervention: Oral paracetamol 1000 mg × 4 + oral ibuprofen 400 mg × 4 + intravenous placebo
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Oral paracetamol 1000 mg × 4 + intravenous dexamethasone 24 mg + oral placebo
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen 400 mg × 4 + intravenous dexamethasone 24 mg + oral placebo
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Oral paracetamol 1000 mg × 4 + oral ibuprofen 400 mg × 4 + intravenous dexamethasone 24 mg
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Placebo (oral and intravenous)
Number of subjects: 1060
Study: 36190744

Group type: EXPERIMENTAL
Intervention: Chronolife smart t-shirt worn daily for 2 weeks (preferably 8 hours per day)
Number of subjects: 20
Study: 36190739

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: H2 antagonists (nizatidine, famotidine, ranitidine)
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: Monoamine modulators (reboxetine, fluoxetine)
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 1388

Group type: COMPARATOR
Intervention: Placebo or no treatment (standard care)
Number of subjects: 1388

Group type: COMPARATOR
Intervention: All agents
Number of subjects: 1388
Study: 36190762

Group type: EXPERIMENTAL
Intervention: Proteinuria
Number of subjects: 576

Group type: COMPARATOR
Intervention: Control (no proteinuria)
Number of subjects: 576
Study: 36190843

Group type: EXPERIMENTAL
Intervention: Baseline eHealth literacy assessment using eHealth Literacy Scale (eHEALS)
Number of subjects: 1970

Group type: EXPERIMENTAL
Intervention: Baseline eHealth literacy
Number of subjects: 1970

Group type: EXPERIMENTAL
Intervention: 2-month follow-up eHealth literacy
Number of subjects: 1970
Study: 36191284

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 907
Study: 36191836

Group type: EXPERIMENTAL
Intervention: Severe pain
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Constant pain
Number of subjects: 488

Group type: COMPARATOR
Intervention: No pain
Number of subjects: 488

Group type: COMPARATOR
Intervention: Mild-moderate pain
Number of subjects: 488
Study: 36192219

Group type: EXPERIMENTAL
Intervention: Sevoflurane (dose not specified)
Number of subjects: 167
Study: 36192231

Group type: EXPERIMENTAL
Intervention: Ovulation Induction (OI) or No Treatment
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Intrauterine Insemination (IUI)
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: In Vitro Fertilization (IVF)
Number of subjects: 2369
Study: 36192237

Group type: EXPERIMENTAL
Intervention: Prexasertib (LY2606368)
Number of subjects: 169
Study: 36192280

Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion Stimulation (DRGS)
Number of subjects: 9
Study: 36192386

Group type: EXPERIMENTAL
Intervention: Sinovac-CoronaVac vaccine
Number of subjects: 0
Study: 36192514

Group type: EXPERIMENTAL
Intervention: Combination intra-peritoneal and systemic chemotherapy
Number of subjects: 0
Study: 36192569

Group type: EXPERIMENTAL
Intervention: Prone positioning with bedside titrated PEEP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supine positioning with bedside titrated PEEP
Number of subjects: 0
Study: 36192606

Group type: EXPERIMENTAL
Intervention: Blood flow restriction - low load strength training (BFR-LLST) added to usual care exercise
Number of subjects: 42
Study: 36192802

Group type: EXPERIMENTAL
Intervention: Financial navigation (FN) intervention
Number of subjects: 780
Study: 36192847

Group type: EXPERIMENTAL
Intervention: octocog alfa (Kovaltry®/BAY 81-8973) prophylaxis regimen
Number of subjects: 302
Study: 36193630

Group type: EXPERIMENTAL
Intervention: Mechanical atherothrombectomy
Number of subjects: 0